

Roche - Media News




Media 1



Basel, 1

06018667

SUPPL



Statement - Label changes for Tamiflu

Tamiflu (oseltamivir phosphate) was demonstrated in clinical trials to be a safe and effective medication for influenza prevention and treatment. Tamiflu was approved in 1999 and has been used by more than 42 million people in over 80 countries.

Roche continuously reviews post-marketing safety information and provides regular updates to the regulatory agencies. Based upon reports received over the last influenza season Roche has agreed that the Tamiflu label in the US will be revised to include reports of neuropsychiatric events such as self-injury and delirium in patients with influenza. Reports of neuropsychiatric events in patients taking oseltamivir are very rare based on usage, and a causal relationship between the use of oseltamivir and the likelihood of neuropsychiatric events in influenza patients cannot be established.

In 2005, 103 psychological reports during treatment of influenza with Tamiflu were received, including 5 deaths. These events are extremely rare in relation to the number of patients treated during the influenza season. Based upon the information presented by the FDA we calculate that:

- approximately 1 in 100'000 patients experienced psychological disorders
- approximately 1 out of 2 million patients treated died

None of these events could be established to have been caused by Tamiflu.

Phase III pivotal trials conducted by Roche found similar reports of neurologic and psychiatric events in pediatric influenza patients being treated with Tamiflu and those receiving no treatment. In addition, a recent review of a US claims database showed no differences in the incidence of neuropsychiatric events between flu patients treated with Tamiflu and those who were not treated.

Influenza itself is a severe disease. High fever, which is a typical symptom of influenza, has been associated with neuropsychaitric disorders including hallucination or delirium.

The well-being of patients and the safe and effective use of our medications is a priority for Roche. Roche continues to monitor the safety of Tamiflu through established reporting mechanisms and notify regulatory authorities of adverse events in line with regulatory requirements.

© 2006 F. Hoffmann-La Roche Ltd

print close

PROCESSED

NOV 24 2006


THOMSON
FINANCIAL

Handwritten signature: JLV 11/22



Media release

Furnished under Rule 12g3-2(b)
ROCHE HOLDING 82-3315




Basel, 16 November 2006

The Salzburg Festival and Roche launch the "Continents..." cultural project

Ground-breaking partnership encourages access to innovation in music and science for young people

The Salzburg Festival and Roche are to establish a joint cultural project in the area of contemporary music: The new "Continents..." series will invite audiences at the Salzburg Festival on a journey of discovery through the compositional and aesthetic universe of prominent 20th/21st century composers. This collaboration between Roche and the Salzburg Festival will primarily allow European university and college students to attend contemporary music events in Salzburg, and will attempt to uncover the link between innovation in music and art on the one hand and science on the other. In addition, new communication channels will be opened up, giving both the Salzburg Festival and Roche access to interesting new target groups.



Roche is supporting the "Continents..." project at the Salzburg Festival as part of its commitment to contemporary music and art and is making a substantial financial contribution that will allow a ticket price reduction of more than 30% for the next five years. Roche will also coordinate the marketing of "Continents..." at university and college level via its own networks and channels and will run a project specifically aimed at upcoming young scientists, "Roche Continents – Youth! Arts! Science!". As part of this project, up to 100 students of science, music and the arts from around the globe will be given the opportunity to spend a week in Salzburg exploring various topics from the world of art and science in a series of workshops.

Speaking of the project, Franz B. Humer, Board Chairman and CEO of Roche, said: "I am absolutely delighted that Roche is able to collaborate with the Salzburg Festival in launching 'Continents...'. This new partnership is a good match with our other successful projects in the area of innovative contemporary music: *Roche Commissions* in Switzerland and the United States, and the international *Roche'n'Jazz* initiative. Through this new project we aim to encourage young

people to explore different aspects of contemporary music and in this way to indirectly heighten their fascination with innovation in general, and scientific innovation in particular."

Helga Rabl-Stadler, President of the Salzburg Festival comments: "Thanks to Roche, the Festival and Markus Hinterhäuser, who came up with the idea for 'Continents...' and who will be responsible for programming the concerts, can pick up where the successful 'Zeitfluss' tradition of the 1990s left off. From 2007, there will once again be a 'festival within the festival'. With its generous five-year commitment, Roche has secured the budget for an important piece of programming. But Roche also stands to gain from its sponsorship of the project. A critical confrontation with New Music can give people the courage to change various aspects of their lives. Young scientists will recognise that art is the real arena in which ideas are being developed today."

"Continents..." will get underway in summer 2007 with the works of the Italian transcendental composer Giacinto Scelsi. Scelsi (1905-1988) was one of the leading exponents of 20th century music. The poetry of Scelsi's music – and this is particularly true of his solo pieces, originally for piano, but later for a whole variety of instruments – is derived from its supreme concentration on a single note and the timbral variations which slowly unfold and evolve. In 2008, the "Continents..." series will focus on Salvatore Sciarrino and in 2009 on Iannis Xenakis.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005 sales by the Pharmaceuticals Division totalled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries. In addition to supporting a large number of humanitarian projects and promoting scientific research, it has a long-standing commitment to contemporary art as a means of expressing innovation. Thus Roche has provided funding for the Mario Botta-designed *Museum Tinguely* in Basel since 1996. It also sponsors *Roche Commissions*, a joint project with the Lucerne Festival, Carnegie Hall and Cleveland Orchestra involving the commissioning and public premiere of new works by contemporary composers, as well as promoting challenging jazz through its international *Roche'n'Jazz* initiative. Additional information about the Roche Group is available on the Internet at www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Further information

- Roche cultural sponsorship: www.roche.com/sus_csoc-resp-arts
- Salzburg Festival www.salzburgfestival.at

Roche Group Media Office

Telephone: +41 61 688 8888 / Email: basel.mediaoffice@roche.com


- Baschi Dürr
- Alexander Klauser
- Daniel Piller (Head Roche Group Media Office)
- Katja Prowald (Head Science Communications)
- Martina Rupp

Furnished under Rule 12g3-2(b)
ROCHE HOLDING 82-3315

Investor Update



Basel, 17 November 2006



FDA approves Herceptin for the adjuvant treatment of HER2-positive node-positive breast cancer

Dear Investor,

Please find attached a Genentech news release announcing that the U.S. Food and Drug Administration (FDA) approved Herceptin (Trastuzumab), as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, for the adjuvant treatment of HER2-positive node-positive breast cancer. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment – surgery with or without radiation therapy – with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.

Please do not hesitate to contact us if you have any further questions.

Roche IR Contacts:

Dr. Karl Mahler
Phone: +41 (0) 61 687 85 03
e-mail: karl.mahler@roche.com

Eva Schäfer-Jansen
Phone: +41 (0) 61 688 66 36
e-mail: eva.schaefer-jansen@roche.com

Dianne Young
Phone: +41 (0) 61 688 93 56
e-mail: dianne.young@roche.com

Dr. Zuzana Dobbie
Phone: +41 (0) 61 688 80 27
e-mail: zuzana.dobbie@roche.com

Carla Bedard
Phone: +41 (0) 61 687 13 00
e-mail: carla_christine.bedard@roche.com

North American investors please contact:
Thomas Kudsk Larsen
Phone: +41 (0) 61 687 05 17
Mobile phone: +41 (0) 79 829 15 07
e-mail: thomas_kudsk.larsen@roche.com

General inquiries:
International: +41 (0) 61 688 8880
North America: +1 973 562 2233
e-mail: investor.relations@roche.com

Genentech **NEWS RELEASE**

Media Contact: Kimberly Ocampo (650) 467-0679
Investor Contact: Sue Morris (650) 225-6523
Advocacy Contact: Ajanta Horan (650) 467-1741

FDA APPROVES HERCEPTIN® FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER

*-- Herceptin Significantly Reduced the Risk of Breast Cancer Recurrence
by 52 Percent in Pivotal Studies --*

*-- Only Targeted Biologic Therapy Approved for Use in Adjuvant and Metastatic
HER2-positive Breast Cancer --*

SOUTH SAN FRANCISCO, Calif. -- Nov. 16, 2006 -- Genentech, Inc. (NYSE: DNA) announced today that the U.S. Food and Drug Administration (FDA) approved Herceptin® (Trastuzumab), as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, for the adjuvant treatment of HER2-positive node-positive breast cancer. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment – surgery with or without radiation therapy – with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.

The FDA approval was based on data from an interim joint analysis of more than 3,500 patients enrolled in two Phase III clinical trials. These results showed that the addition of Herceptin to standard adjuvant therapy significantly reduced the risk of breast cancer recurrence, the primary endpoint of the studies, by 52 percent (or a hazard ratio of 0.48) in women with HER2-positive breast cancer, compared to those patients who received standard adjuvant therapy alone.

“The results of the joint analysis show that, for women with early-stage HER2-positive breast cancer, the addition of Herceptin to chemotherapy reduces the relative risk of breast cancer recurrence by approximately half, which translates into fewer women dying from one of the most aggressive types of breast cancer,” said Edward Romond, M.D., Professor of

Medicine, Division of Hematology/Oncology at the University of Kentucky. "This is the largest improvement in outcome for any group of women with breast cancer in 25 years."

"Our work with Herceptin exemplifies our commitment to developing the right drug for the right patient. We designed Herceptin for the approximately 25 percent of women whose breast cancers overexpress HER2 because we believed that we could make a significant impact for these patients battling a very aggressive, difficult-to-treat disease," said Susan Desmond-Hellmann, M.D., M.P.H., Genentech's president, product development. "These adjuvant studies showed that, in women with HER2-positive lymph node-positive breast cancer, Herceptin reduces the risk of developing metastatic disease, which could benefit thousands of lives worldwide each year."

"This approval also highlights a first step in a major initiative to conduct studies of Genentech targeted therapies in earlier stages of disease where they have the potential to have the greatest impact," added Desmond-Hellmann.

After three-and-a-half years in the study, 87 percent of women treated with Herceptin plus chemotherapy were disease free, compared to 71 percent of women treated with chemotherapy alone. A survival analysis conducted after patients had been followed for a median of 24 months showed a 33 percent reduction in the risk of death (based on a hazard ratio of 0.67), which is equivalent to a 49 percent improvement in overall survival.

Each study had an independent external Data Monitoring Committee (DMC) that reviewed data from the studies, including cardiac safety data, on a regular basis. According to the investigators, serious or life-threatening (and in rare cases, fatal) cardiac events, most commonly congestive heart failure (weakening of the heart muscle), occurred approximately 3 to 4 percent more often in the Herceptin plus standard therapy arms than in the standard therapy alone arms. Other adverse events reported in both studies included dyspnea and interstitial pneumonitis, which occurred at a rate of less than 1 percent.

"Today's approval is wonderful news for women with early-stage HER2-positive breast cancer and another significant milestone in the Herceptin story," said Fran Visco, president of the National Breast Cancer Coalition. "Thanks to the thousands of breast cancer patients, clinical investigators, the FDA, Genentech and advocates, who have all played critical roles in Herceptin's development, we now have a treatment option that represents a major advance for women with HER2-positive breast cancer before the disease has metastasized. We look

forward to continuing our collaboration with Genentech on future Herceptin research.”

Additional Background on the Joint Analysis Studies

The two Phase III trials were sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the North Central Cancer Treatment Group (NCCTG), in collaboration with the Cancer and Leukemia Group B, the Eastern Cooperative Oncology Group and the Southwest Oncology Group.

These randomized, controlled trials studied four cycles of doxorubicin (adriamycin) and cyclophosphamide followed by paclitaxel, either every three weeks or weekly for 12 weeks, compared with the same regimen plus 52 weeks of Herceptin beginning with the first dose of paclitaxel.

The joint analysis results were first presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) in May 2005 and subsequently published in *The New England Journal of Medicine* (NEJM) in October 2005.

About Herceptin

Herceptin is a targeted therapeutic antibody treatment for women who have tumors that overexpress the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer is an especially aggressive form of the disease that affects approximately one-fourth of women with breast cancer. Research has shown that women with HER2-positive breast cancer have a greater likelihood of recurrence, poorer prognosis and decreased survival compared to women with HER2-negative breast cancer. Special testing is required to identify women who have HER2-positive breast cancer and who may be candidates for treatment with Herceptin.

Herceptin is the only targeted biologic therapy approved for treatment of HER2-positive breast cancer in the adjuvant and metastatic settings. Herceptin first received FDA approval in September 1998 for use in women with metastatic breast cancer. In this setting, it is indicated for treatment of patients both as a first-line therapy in combination with paclitaxel and as a single agent in second- and third-line therapy.

In clinical trials of HER2-positive metastatic breast cancer patients, Herceptin in

combination with chemotherapy (paclitaxel) was the first anti-HER2 agent to demonstrate an improvement in survival in a Phase III trial. In December 2001, Genentech received FDA approval to include, in the product label, data that showed an improved median overall survival for women with HER2-positive metastatic breast cancer treated initially with *Herceptin and chemotherapy, compared to chemotherapy alone* (median 25.1 months compared to 20.3 months).

Herceptin Safety Profile

Herceptin administration can result in left ventricular dysfunction and congestive heart failure (CHF). The incidence and severity of left ventricular cardiac dysfunction/CHF were highest in patients who received Herceptin concurrently with anthracycline-containing chemotherapy regimens.

Herceptin should be discontinued in patients receiving adjuvant therapy for breast cancer who develop a clinically significant decrease in left ventricular function. In patients with metastatic breast cancer who develop a clinically significant decrease in left ventricular function, discontinuation of Herceptin should strongly be considered.

Serious infusion reactions and pulmonary toxicity have occurred; rarely these have been fatal. Discontinuation of Herceptin should be strongly considered for infusion reactions manifesting as anaphylaxis, angioedema, pneumonitis, or acute respiratory distress syndrome.

Exacerbation of chemotherapy-induced neutropenia has also occurred.

The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea (shortness of breath), rash, neutropenia (decrease in the number of neutrophils, a type of white blood cell), anemia, and myalgia (muscle pain).

About Breast Cancer

According to the American Cancer Society, 212,920 women in the United States will be diagnosed with breast cancer in 2006, and 40,970 will die from the disease. Excluding skin cancer, breast cancer is the most common form of cancer among women and the second-leading cancer killer among women, after lung cancer. The chance of a woman having invasive breast cancer some time during her life is about 1 in 8.

The chance of dying from breast cancer is about 1 in 33. Breast cancer death rates are going down. This decline is probably the result of finding the cancer earlier and improved treatment.

Genentech's Commitment to Patient Access

Genentech is committed to assisting eligible patients in accessing our therapies for approved indications, regardless of their ability to pay. Although Genentech's products are covered by most government and private insurance, Genentech established the Genentech® Access to Care Foundation (GATCF) in 1990 for its marketed products. GATCF donates product to eligible patients in the United States who are uninsured or deemed uninsured due to payor denial, except for Pulmozyme® (dornase alfa, recombinant), which is covered by the Genentech Endowment for Cystic Fibrosis. In 2005 alone, GATCF supported over 18,000 patients by providing approximately \$200 million of free product. In addition, Genentech recently doubled to \$50 million its donation to several independent public charities that provide financial assistance to eligible patients who cannot access needed medical treatment due to co-pay costs. To learn more about potential financial assistance options, patients can speak with an Alternative Funding Specialist from Genentech's Single Point of Contact (SPOC) group by calling 866-724-9394 or visiting <http://www.SPOCOnline.com>.

About Genentech BioOncology

Genentech is committed to changing the way cancer is treated by establishing a broad oncology portfolio of innovative, targeted therapies with the goal of improving patients' lives. The company is the leading provider of anti-tumor therapeutics in the United States.

Genentech is conducting clinical development programs for Rituxan® (Rituximab), Herceptin® (Trastuzumab), Avastin® (bevacizumab), and Tarceva® (erlotinib), and markets all four products in the United States, either alone (Avastin and Herceptin) or with Biogen Idec Inc. (Rituxan) or OSI Pharmaceuticals, Inc. (Tarceva). For sale outside of the United States, Genentech has licensed Rituxan, Herceptin, and Avastin to Roche, and OSI Pharmaceuticals has licensed Tarceva to Roche.

The company has a robust pipeline of potential oncology therapies with a focus on four key areas: angiogenesis, apoptosis (i.e., programmed cell death), the HER pathway, and B-

cell biology. An investigational antibody directed at the HER pathway is currently in Phase II trials. In early development, are a small molecule directed at the hedgehog pathway and an investigational agent targeting apoptosis.

Founded 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit <http://www.gene.com>.

###

For full prescribing information, including Boxed WARNINGS for Herceptin, please call 800-821-8590 or visit <http://www.gene.com>.